Thought it was easy money
could be, johny. would not surprise me. How low you gonna drive this? i want in at 2.50
Good post, Tursta. There is a lot of enthusiasm with IDRA, and I view it as a long-term grandslam. However, there is heavy short interest in the interim. GSO's will send this to the moon forever. but the IND work won't be done until next year. It starts 2H2015 per 10Q. They do have long history of 2nd gen data and its pioneer to shorten this. I think 1H2016 into the clinic with Phase 1/2 results 2016-2017. By then, Phase 3 will be done for WM, DLBCL, Dermotomyositis, and collaboration trials. I'm exercising patience with this diamond and averaging down when big-money shorts drive it that way. Use 'em.
I can't see that being anything but great news, or they wouldn't add risk. It's working. The doctors are telling other patients and the company. And the patients are begging for it because this study is only for patients who have tried EVERYTHING else. Fantastic find. Still expecting volatility but a heckuva spike into results and beyond. Thanks, Mitch.
Doing alright, Bird. Same for you. Hoping to get some more shares in the 2s. What do you think? Should be a monster run on WM through 2016.
It's a good post. Objective. Low 2s would be VERY nice. Fundamentally long-term grandslam.
Double the stock options at 3.59 exercise price. 70,000. Long term, great entry here. Short term, possibly get it lower. Sooner or later, insiders will make their millions as usual.
Thanks, bio. I've been following GHDX closely for years. Management is solid and upfront. First half of this year will be red because they have been expanding infrastructure deliberately according to plan. 2nd half they'll be turning it up. They've invested heavily in prostate launch and coverage, and they've succeeded. Prostate DX sales tripled first quarter. That market is huge, and they've got it clicking on all cylinders. FMR may have decided to move their money until end of year. I see a GEVA run coming late this year into next. I'll continue to add when the market blindly punishes it for 2nd quarter loss. Next 6 quarters expect huge move or sale. They are trading at a ridiculous 3:1 sales. There are only 3 million shares that tutes don't own, so we know Bakers control the show here. When prostate really kicks in, along with first liquid biopsy on market in 2016, she's worth 2-5 bill MC, or 75-150/sh.
Yeah, I'm thinking 20 2016 into 2017 when WM finishes Ph3 and GSO's finish Phase 2. After that, she's going to space.